Regeneron Pharmaceuticals Inc $310.27

up +4.25


23/7/2014 04:00 PM  |  NASDAQ : REGN  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get REGN Trend Analysis - it has underperformed the S&P 500 by 7%

Partner Headlines

  1. Stocks Recover Impressively; Gap Slumps In After Hours

    IBD
  2. Regeneron's Dupilumab Drug Headed For Phase Three Tests

    IBD
  3. Market Slides On European Bank Worries; Gold Stocks Rise

    IBD
  4. UPDATE: Morgan Stanley Reiterates On Regeneron Pharmaceuticals Following ...

    Benzinga
  5. Benzinga's Top #PreMarket Gainers

    Benzinga
  6. UPDATE: Regeneron, Sanofi Offer Positive Results from Phase 2b Study of ...

    Benzinga
  7. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  8. Pharmas Soar To New Highs

    IBD
  9. Salix, Akorn, Regeneron Lead Drug Stock Rally

    IBD
  10. Stocks Rise In Strong Turnover; Netflix Soars On Upgrade

    IBD
  11. Regeneron Rises As Sanofi Raises Stake In Biotech

    IBD
  12. Bristol-Myers, Pfizer, Regeneron Drugs Get EU Nods

    IBD
  13. US Stock Futures Drop Ahead Of Consumer Sentiment Report

    Benzinga
  14. EYLEA Injection Recommended For Approval Regarding Treatment Of Visual ...

    Benzinga
  15. Auxilium Acquiring QLT For New Products, Low Taxes

    IBD
  16. Major Indexes Narrowly Lower As Actavis Rallies

    IBD
  17. Regeneron Shares Fall Following BMO's Note Of Roche Preference

    Benzinga
  18. US Stock Futures Edge Higher Ahead Of Jobless Claims, Retail Sales Data

    Benzinga
  19. US Stock Futures Tumble; World Bank Lowers Global Growth Outlook

    Benzinga
  20. Valeant EPS Tops, Sales Miss

    IBD
  21. Valeant Reports Mixed Q1 Amid Drug Earnings Bonanza

    IBD
  22. Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed

    IBD
  23. Bristol, Merck, Sanofi Report Soft Q1 Sales

    IBD
  24. RBC Optimistic on Regeneron Following Lower Sales by Novartis' Lucentis

    Benzinga
  25. UPDATE: Canaccord Genuity Initiates Coverage on Regeneron Pharmaceuticals ...

    Benzinga
  26. Benzinga's Top Initiations

    Benzinga
  27. Top 40 Upcoming Earnings Releases

    Benzinga
  28. Biotechs Struggling To Find A Bottom

    Benzinga
  29. Nasdaq Sheds 1% As China Growth Names, Biotechs Fall Hard

    IBD
  30. S&P 500 Edges Lower As Biotech Selling Weighs On Nasdaq

    IBD
  31. Cholesterol drug meets goal

    IBD
  32. Nasdaq Leads Another Up Day; S&P 500 Hits All-Time High

    IBD
  33. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  34. Gilead Adds To Biotech Woes

    IBD
  35. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  36. Rebound Rally Losing More Steam; BitAuto Hangs Tough

    IBD
  37. New Cholesterol Fighters To Take Center Stage At ACC

    IBD
  38. Market Wrap For March 27: Markets Lower Following Mixed Economic Data

    Benzinga
  39. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga
  40. US Stock Futures Rise; GDP, Jobless Claims Data In Focus

    Benzinga
  41. Netflix, Other Big Cap Growth Stocks Offer Buy Points

    IBD
  42. Amgen's PCSK9 Scores Against Genetic High Cholesterol

    IBD
  43. UPDATE: Citigroup Upgrades Regeneron Pharmaceuticals

    Benzinga
  44. Regeneron falls on FDA probe

    IBD
  45. Nasdaq Lags As Stock Market Closes Lower

    IBD
  46. Early Gains Fade; E-House Breaks Out But Biotechs Stumble

    IBD
  47. Regeneron Cholesterol-Drug Worries Ding Stock

    IBD
  48. Ukraine Unrest Sparks Selling But Some Biotechs Firm Up

    IBD
  49. Regeneron CEO Sees Surge

    IBD
  50. Regeneron Pipeline Could Be The Big Story In 2014

    IBD
Trading Center